Impact of hematocrit on morbidity and mortality - PubMed (original) (raw)
Affiliations
- PMID: 10928336
Review
Impact of hematocrit on morbidity and mortality
A J Collins et al. Semin Nephrol. 2000 Jul.
Abstract
It has been 10 years since epoetin-alpha was approved by the federal Food and Drug Administration for use in end-stage renal disease patients. Over this period of time, clinical studies have shown a relationship between the correction of anemia and improved cardiac function, cognitive ability, sexual function, and exercise capacity. Recent large epidemiological studies have shown that mortality and morbidity are reduced when the hematocrit (Hct) level is in the range 33% to 36%, and the National Kidney Foundation's Dialysis Outcomes Quality Initiative (NKF-DOQI) guidelines recommend a target Hct of 33% to 36% to enhance patient outcomes. The most recent mortality studies show that Hcts less than 30% (or hemoglobins less than 110 gm/L) are associated with an 18% to 40% increased associated risk of death and hospitalizations. Higher Hcts in the 33% to 36% range appear to be associated with a 7% reduced risk of death and hospitalizations compared with patients with Hcts of 30% to less than 33%. Patients with sustained Hcts of 33% to 36% over 1 year appear to have the best outcome compared with patients with Hcts that fall. These studies suggest that the factors that may influence patients' ability to move into higher Hct ranges need to be determined to enhance patient outcomes. Dramatic improvement in hemodialysis patient Hct levels has occurred since 1989. Mortality and hospitalization studies support the NKF-DOQI target Hct range of 33% to 36% as providing the best associated outcomes.
Similar articles
- Association between hematocrit level and mortality in hemodialysis patients. Case study of the anemic patient.
Collins A, Ellefson J. Collins A, et al. Nephrol Nurs J. 2000 Apr;27(2):233-6. Nephrol Nurs J. 2000. PMID: 11111551 - Appropriate hematocrit levels of erythropoietin supplementary therapy in end-stage renal failure complicated by coronary artery disease.
Nagao K, Tsuchihashi K, Ura N, Nakata T, Shimamoto K. Nagao K, et al. Can J Cardiol. 1997 Aug;13(8):747-53. Can J Cardiol. 1997. PMID: 9284841 Review. - Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998.
Kimmel PL, Greer JW, Milam RA, Thamer M. Kimmel PL, et al. Semin Nephrol. 2000 Jul;20(4):335-44. Semin Nephrol. 2000. PMID: 10928335 - Anemia management practices in peritoneal dialysis patients. Case study of the anemic patient.
MacCracken MA. MacCracken MA. Nephrol Nurs J. 2001 Aug;28(4):435-8. Nephrol Nurs J. 2001. PMID: 12143466 Review.
Cited by
- Physician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study.
Yang JY, Shu KH, Peng YS, Hsu SP, Chiu YL, Pai MF, Wu HY, Tsai WC, Tung KT, Kuo RN. Yang JY, et al. JMIR Form Res. 2023 May 3;7:e44373. doi: 10.2196/44373. JMIR Form Res. 2023. PMID: 37133912 Free PMC article. - Multi-head self-attention mechanism enabled individualized hemoglobin prediction and treatment recommendation systems in anemia management for hemodialysis patients.
Yang JY, Lee TC, Liao WT, Hsu CC. Yang JY, et al. Heliyon. 2023 Feb 1;9(2):e12613. doi: 10.1016/j.heliyon.2022.e12613. eCollection 2023 Feb. Heliyon. 2023. PMID: 36747539 Free PMC article. - Recovery of vision after treatment of hemodialysis related bilateral optic nerve ischemia.
Paez-Escamilla M, Abo-Zed A, Abramovitz B, Stefko ST, Waxman E. Paez-Escamilla M, et al. Am J Ophthalmol Case Rep. 2022 Jan 29;25:101373. doi: 10.1016/j.ajoc.2022.101373. eCollection 2022 Mar. Am J Ophthalmol Case Rep. 2022. PMID: 35146214 Free PMC article. - Hypochromic red cells as predictors of anemia in patients undergoing hemodialysis: an observational retrospective study.
Kee YK, Jeon HJ, Oh J, Shin DH. Kee YK, et al. Sci Rep. 2021 Dec 20;11(1):24215. doi: 10.1038/s41598-021-03746-2. Sci Rep. 2021. PMID: 34931015 Free PMC article. - Clinical Implications of the Coexistence of Anemia and Diabetes Mellitus in the Elderly Population.
Michalak SS, Wolny-Rokicka E, Nowakowska E, Michalak M, Gil L. Michalak SS, et al. J Diabetes Res. 2021 Oct 18;2021:8745968. doi: 10.1155/2021/8745968. eCollection 2021. J Diabetes Res. 2021. PMID: 34708130 Free PMC article.